Diagnostic accuracy of multiparametric magnetic resonance imaging (MRI) in patients with suspected prostate cancer

Multiparametric MRI for prostate cancer diagnosis

Abstract

BACKGROUND & OBJECTIVE: In addition to reducing the frequency of needless biopsies, multiparametric MRI (mpMRI) has a high sensitivity and specificity in identifying clinically relevant tumors. The goal of this study was to find out how accurate multiparametric MRI is at finding prostate cancer.

METHODOLOGY: Between March 1, 2023, and February 28, 2024, 123 male patients with suspected prostate cancer, ages 50 to 90, participated in this cross-sectional validation study. Patients with active urinary tract infections were excluded from immediate TRUS-guided biopsy because of the acute infection and post-biopsy urosepsis risk. A multiparametric MRI was generated at an outpatient diagnostic clinic. To achieve thorough coverage and precise imaging of the prostate gland, the mpMRI protocol used an 8-Channel Body Array coil and included T2-weighted imaging, diffusion-weighted imaging with ADC maps, and dynamic contrast-enhanced imaging; additional anatomical/localizer sequences were used only for localization. The mpMRI diagnostic indicators' sensitivity, specificity, accuracy, PPV, and NPV were analyzed.

RESULTS:  Overall, mpMRI's sensitivity was 84.93%, specificity was 84.0%, PPV was 88.57%, NPV was 79.25%, and diagnostic accuracy was 84.55% when compared to TRUS-guided biopsy.

CONCLUSION: This study shows that prostate cancer can be detected with a very high degree of diagnostic accuracy using multiparametric MRI.